| Literature DB >> 35805241 |
Cara Symanzik1, Patricia Weinert1, Željka Babić2, Sarah Hallmann3, Martin Stibius Havmose4, Jeanne Duus Johansen4, Sanja Kezic5, Marija Macan2, Jelena Macan2, Julia Strahwald3, Rajka Turk2, Henk F van der Molen5, Swen Malte John1, Wolfgang Uter3.
Abstract
The safety assessment of cosmetics considers the exposure of a 'common consumer', not the occupational exposure of hairdressers. This review aims to compile and appraise evidence regarding the skin toxicity of cysteamine hydrochloride (cysteamine HCl; CAS no. 156-57-0), polyvinylpyrrolidone (PVP; CAS no. 9003-39-8), PVP copolymers (CAS no. 28211-18-9), sodium laureth sulfate (SLES; CAS no. 9004-82-4), cocamide diethanolamine (cocamide DEA; CAS no. 68603-42-9), and cocamidopropyl betaine (CAPB; CAS no. 61789-40-0). A total of 298 articles were identified, of which 70 were included. Meta-analysis revealed that hairdressers have a 1.7-fold increased risk of developing a contact allergy to CAPB compared to controls who are not hairdressers. Hairdressers might have a higher risk of acquiring quantum sensitization against cysteamine HCl compared to a consumer because of their job responsibilities. Regarding cocamide DEA, the irritant potential of this surfactant should not be overlooked. Original articles for PVP, PVP copolymers, and SLES are lacking. This systematic review indicates that the current standards do not effectively address the occupational risks associated with hairdressers' usage of hair cosmetics. The considerable irritant and/or allergenic potential of substances used in hair cosmetics should prompt a reassessment of current risk assessment practices.Entities:
Keywords: cocamide diethanolamine; cocamidopropyl betaine; cosmetics; cysteamine hydrochloride; hairdresser; hairdressing; hand eczema; polyvinylpyrrolidone; polyvinylpyrrolidone copolymers; sodium laureth sulfate
Mesh:
Substances:
Year: 2022 PMID: 35805241 PMCID: PMC9265752 DOI: 10.3390/ijerph19137588
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Eligibility criteria following the PECOS scheme.
| Criterion | Inclusion | Exclusion |
|---|---|---|
| Hairdressers, Patients, Products | None | |
| Exposure to (an) eligible chemical(s) † | n/a | |
| Clients, Consumers, normal Population (no or less exposure) | n/a | |
| Skin toxicity event (contact allergy, irritancy) | n/a | |
| Experimental studies | Other qualitative studies | |
| Observational studies | ||
| Case reports | ||
| Case series |
† cysteamine hydrochloride (cysteamine HCl), usually used in perming solutions and also in hair dyes, polyvinylpyrrolidone (PVP) and polyvinylpyrrolidone (PVP) copolymers, which are used as film-forming components in, e.g., hairspray, as well as sodium laureth sulfate (SLES), cocamide diethanolamine (cocamide DEA), and cocamidopropyl betaine (CAPB), which are used as detergents in cosmetic applications.
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020, flow diagram of literature search according to Page et al. [38].
Publication record forms (PRFs) of original articles for cysteamine hydrochloride (cysteamine HCl).
| Study | Year (Range) | Country | Study Design | Patch Testing | Patch Testing Context | Population Tested | Female (%) | Age (Years) | No. of Hairdresser Tested | No. of Hairdressers with a Positive Result | No. of Others Tested | No. of Others Tested with a Positive Result |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ito et al. [ | 2012–2014 | Japan | epidemiological sample | yes | patch test special series | all patch-tested patients | 87 | 58 (mean) | n/a | n/a | 192 | 26 |
| Schwensen et al. [ | 2002–2011 | Denmark | epidemiological sample | yes | patch test special series | hairdressers | 83 | 30.8 (mean) | 12 | 1 | n/a | n/a |
n/a, not applicable.
Publication record forms (PRFs) of case series and case reports for cysteamine hydrochloride (cysteamine HCl).
| Study | Year (Range) | Country | Sex | Age | Occupation | Working Years | Own Products Tested |
|---|---|---|---|---|---|---|---|
| Isaakson and van der Walle [ | 2007 | Sweden | 1 female | 53 | hairdresser | 27 | permanent-wave solution |
| Landers, Law, and Storrs [ | 2002 | USA | 1 female | 38 | hairdresser | n/a | permanent-wave solution |
| Nishioka, Koizumi, and Takita [ | 2012–2017 | Japan | 4 females | 22 to 73 | hairdresser | n/a | n/a |
n/a, not applicable; USA, United States of America.
Publication record forms (PRFs) of case reports for polyvinylpyrrolidone (PVP) copolymers.
| Study | Year (Range) | Country | Sex | Age | Occupation | Working Years | Own Product Tested |
|---|---|---|---|---|---|---|---|
| Buonomo and Warshaw [ | 2021 | USA | 1 female | 25 | n/a | n/a | moisturizer |
| Pastor et al. [ | 2008 | Spain | 1 female | 20 | n/a | n/a | lipstick |
| Quartier et al. [ | 2006 | Belgium | 1 female | 28 | n/a | n/a | lipstick |
| Scheman and Cummins [ | 1998 | USA | 1 female | 53 | n/a | n/a | skin care products |
n/a, not applicable; USA, United States of America.
Publication record forms (PRFs) of original articles for cocamide diethanolamine (cocamide DEA).
| Study | Year (Range) | Country | Study Design | Patch Testing | Patch Testing Context | Population Tested | Female (%) | Age (years) | No. of Hairdresser Tested | No. of Hairdressers with a Positive Result | No. of Others Tested | No. of Others Tested with a Positive Result |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mertens, Gilissen, and Goossens [ | 1990–2015 | Belgium | monocentric retrospective study | yes | epidemiological sample | all patch-tested patients | n/a | n/a | n/a | 6 | 1767 | 18 |
| Aalto-Korte et al. [ | 1993–2011 | Finland | monocentric retrospective study | yes | epidemiological sample | occupational patch-tested patients | n/a | n/a | n/a | n/a | 2572 | 25 |
| Warshaw et al. [ | 2001–2004 | USA | multicentric retrospective study | yes | consecutive patient | all patch-tested patients | 66 | n/a | n/a | n/a | 609 | 28 |
| Davis et al. [ | 2001–2005 | USA | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | 66.8 | 55.1 (mean) | n/a | n/a | 410 | 1 |
| Toholka et al. [ | 2001–2010 | Australia | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | 65 | 40 (mean) | n/a | n/a | 4297 | 1 |
| Warshaw et al. [ | 2003–2004 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 65.2 | 47.5 (mean) | n/a | n/a | 5137 | 56 |
| Fransway et al. [ | 2007–2008 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 64.3 | n/a | n/a | n/a | 5082 | 4 |
| Warshaw et al. [ | 2009–2010 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 77.9 | 48.4 (mean) | n/a | n/a | 4304 | 1 |
| Sundquist, Yang, and Pasha [ | 2010–2016 | Canada | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | 71.1 | 4 to 92 | n/a | n/a | 385 | 3 |
| Warshaw et al. [ | 2011–2012 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 68.6 | 50 (mean) | n/a | n/a | 4230 | 4 |
| Veverka et al. [ | 2011–2015 | USA | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | 67.4 | 53.4 (mean) | n/a | n/a | 2573 | 2 |
| DeKoven et al. [ | 2013–2014 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 70 | 50 (mean) | n/a | n/a | 4859 | 1 |
| DeKoven et al. [ | 2015–2016 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 72 | 50 (mean) | n/a | n/a | 5594 | 2 |
| Grey et al. [ | 2015–2016 | USA | others | yes | patch test special series | all patch-tested patients | 78.7 | 55.2 (mean) | n/a | n/a | 47 | 4 |
n/a, not applicable, USA, United States of America.
Summary of patch test results of original articles regarding cocamide diethanolamine (cocamide DEA).
| Study | Study Period | Country | Positive Results for Cocamide DEA |
|---|---|---|---|
| DeKoven et al. [ | 2013–2014 | USA | 1 of 4859 (0.02%) |
| Toholka et al. [ | 2001–2010 | Australia | 1 of 4297 (0.02%) |
| Warshaw et al. [ | 2001–2004 | USA | 1 of 4304 (0.02%) |
| DeKoven et al. [ | 2015–2016 | USA | 2 of 5594 (0.04%) |
| Warshaw et al. [ | 2011–2012 | USA | 4 of 64,230 (0.1%) |
| Veverka et al. [ | 2011–2015 | USA | 2 of 2573 (0.1%) |
| Fransway et al. [ | 2007–2008 | USA | 4 of 5082 (0.1%) |
| Davis et al. [ | 2001–2005 | USA | 1 of 410 (0.2%) |
| Sundquist, Yang, and Pasha [ | 2010–2016 | Canada | 3 of 385 (0.8%) |
| Mertens, Gilissen, and Goossens [ | 1990–2015 | Belgium | 18 of 1767 (1.0%) |
| Aalto-Korte et al. [ | 1993–2011 | Finland | 25 of 2572 (1.0%) |
| Warshaw et al. [ | 2003–2004 | USA | 56 of 5137 (1.1%) |
| Warshaw et al. [ | 2009–2010 | USA | 28 of 609 (4.6%) |
Cocamide DEA, cocamide diethanolamine; USA, United States of America.
Publication record forms (PRFs) of case series and case reports for cocamide diethanolamine (cocamide DEA).
| Study | Year (Range) | Country | Sex | Age | Occupation | Working Years | Own Product Tested |
|---|---|---|---|---|---|---|---|
| Fowler [ | 1997 | USA | 1 female | 40 | n/a | n/a | personal care products |
| Dejobert et al. [ | 2005 | France | 1 female | 27 | n/a | n/a | shampoo |
| Badaoui et al. [ | 2012–2014 | France | 4 females | 51.6 (mean) | n/a | n/a | mycoster cream, |
n/a, not applicable; USA, United States of America.
Publication record forms (PRFs) of original articles for cocamidopropyl betaine (CAPB).
| Study | Year (Range) | Country | Study Design | Patch Testing | Patch Testing Context | Population Tested | Female (%) | Age (years) | No. of Hairdresser Tested | No. of Hairdressers with a Positive Result | No. of Others Tested | No. of Others Tested with a Positive Result |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| De Groot, van der Walle, and Weyland [ | 1991–1994 | Netherlands | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | 217 | 8 | 564 | 9 |
| Armstrong et al. [ | 1991–1998 | UK | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | 184 | 1 | 10,614 | 28 |
| Uter et al. [ | 1995–2002 | Austria, Germany, Switzerland | multicentric retrospective study | yes | epidemiological sample | hairdressers | 100 | 24 (mean) | 884 | 27 | 1217 | 24 |
| Uter et al. [ | 2003–2006 | Germany | multicentric retrospective study | yes | epidemiological sample | hairdressers | 100 | 26 (mean) | 432 | 14 | 614 | 17 |
| Uter et al. [ | 2007–2012 | Austria, Germany, Switzerland | multicentric retrospective study | yes | epidemiological sample | hairdressers | 100 | 24 (mean) | 744 | 22 | 1903 | 37 |
| Van der Walle and Brunsveld [ | 1989–1992 | Netherlands | monocentric retrospective study | yes | epidemiological sample | hairdressers | 92.2 | 16 to 52 | 103 | 4 | n/a | n/a |
| Lyons et al. [ | 1993–2010 | Australia | monocentric retrospective study | yes | epidemiological sample | hairdressers | 96 | 23 (mean) | 164 | 1 | n/a | n/a |
| Schwensen et al. [ | 2002–2011 | Denmark | epidemiological sample | yes | epidemiological sample | hairdressers | n/a | 16 to 79 | 287 | 1 | 1995 | n/a |
| Krecisz, Kiec-Swierczynska, and Chomiczewska [ | 2011 | Poland | epidemiological sample | yes | patch test special series | hairdressers | 96 | 18 (mean) | 139 | 1 | n/a | n/a |
| Carøe, Ebbehøj, and Agner [ | 2006–2011 | Denmark | epidemiological sample | yes | epidemiological sample | hairdressers | 99.7 | 25 (mean) | 381 | 18 | n/a | n/a |
| Hillen, Grabbe, and Uter [ | 1993–2003 | Germany | multicentric retrospective study | yes | epidemiological sample | all patch-tested patients | n/a | n/a | n/a | n/a | 1021 | 48 |
| Patel and Belsito [ | 1995–2005 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | n/a | n/a | 1831 | 35 |
| Hasan et al. [ | 1995–1997 | Finland | multicentric retrospective study | yes | patch test special series | all patch-tested patients | n/a | n/a | n/a | n/a | 2036 | 30 |
| Saripalli, Achen, and Belsito [ | 1995–2001 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | n/a | n/a | 898 | 17 |
| Schnuch et al. [ | 1996–2009 | Germany | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | n/a | n/a | 83,864 | 1.812 |
| Boonchai, Desomchoke, and Iamtharachai [ | 1999–2008 | Thailand | monocentric retrospective study | yes | epidemiological sample | all patch-tested patients | 81 | 8 to 84 | n/a | n/a | 1247 | 121 |
| Wang et al. [ | 2000–2008 | USA | multicentric retrospective study | yes | patch test special series | all patch-tested patients | 94.8 | 53.8 (mean) | n/a | n/a | 206 | 9 |
| Pratt et al. [ | 2001–2002 | USA | Multicentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | n/a | n/a | 4887 | 137 |
| Warshaw et al. [ | 2001–2004 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 66 | 49.3 (mean) | n/a | n/a | 6621 | 84 |
| Davis et al. [ | 2001–2005 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 66.8 | 55.1 (mean) | n/a | n/a | 1093 | 49 |
| Toholka et al. [ | 2001–2010 | Australia | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | 65 | 41 (mean) | n/a | n/a | 4297 | 292 |
| Warshaw et al. [ | 2001–2016 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | n/a | n/a | 38,775 | 250 |
| Suuronen, Pesonen, and Aalto-Korte [ | 2002–2009 | Finland | monocentric retrospective study | yes | epidemiological sample | all patch-tested patients | n/a | n/a | n/a | n/a | 1092 | 2 |
| Warshaw et al. [ | 2003–2004 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 65.2 | n/a | n/a | n/a | 5137 | 94 |
| Li [ | 2005–2006 | China | monocentric retrospective study | yes | patch test special series | all patch-tested patients | 75 | 9 to 81 | n/a | n/a | 429 | 42 |
| Tomar et al. [ | 2005 | India | monocentric retrospective study | yes | epidemiological sample | all patch-tested patients | 70 | 16 to 55 | n/a | n/a | 50 | 2 |
| Fransway et al. [ | 2007–2008 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | n/a | n/a | 5082 | 56 |
| Tam et al. [ | 2007–2016 | USA | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | 73.4 | 47.7 (mean) | n/a | n/a | 2316 | 12 |
| Warshaw et al. [ | 2009–2010 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | 67.9 | 48.4 (mean) | n/a | n/a | 4304 | 4 |
| Salverda et al. CAPB [ | 2009–2011 | Netherlands | other (cosmetovigilance) | yes | consecutive patients | n/a | n/a | 41 (mean) | n/a | n/a | n/a | n/a |
| Sundquist, Yang, and Pasha [ | 2010–2016 | Canada | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | 71.1 | 4 to 92 | n/a | n/a | 555 | 2 |
| Gregoriou et al. [ | 2010–2019 | Greece | monocentric retrospective study | yes | patch test special series | all patch-tested patients | 89.5 | 13 to 87 | 136 | 20 | 226 | 11 |
| Veverka et al. [ | 2011–2015 | USA | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | 67.4 | 53.4 (mean) | n/a | n/a | 2573 | 58 |
| DeKoven et al. exposure [ | 2013–2014 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | n/a | n/a | 4859 | 77 |
| Garg et al. [ | 2013–2015 | India | monocentric retrospective study | yes | consecutive patients | all patch-tested patients | 86.2 | 36.3 (mean) | n/a | n/a | 58 | 1 |
| DeKoven et al. [ | 2015–2016 | USA | multicentric retrospective study | yes | consecutive patients | all patch-tested patients | n/a | n/a | n/a | n/a | 5592 | 89 |
n/a, not applicable; UK, United Kingdom; USA, United States of America.
Figure 2Forest plot quantifying the risk of cocamidopropyl betaine (CAPB) contact allergy diagnosed by patch testing associated with being a hairdresser vs. other (non-specified) occupation/exposure. De Groot et al. restricted “positive” reactions to “clinically relevant positive” reactions [26]; Armstrong et al. compared hairdressers to consecutively patch-tested patients [25]; and the three Uter et al. studies compared female hairdressers to female patients with suspected contact dermatitis to hair cosmetics—mostly dyes, bleaches, and waving products [22,23,24].
Figure 3Forest plot depicting the prevalence of cocamidopropyl betaine (CAPB) contact allergy diagnosed by patch testing in hairdressers [6,48,50,56,62].
Figure 4Forest plot depicting the prevalence of cocamidopropyl betaine (CAPB) contact allergy diagnosed by patch testing in patients other than hairdressers or with non-specified occupation/exposure [39,40,41,42,43,44,46,49,51,52,54,55,57,58,59,60,61,63,64,65,66,67,68].
Publication record forms (PRFs) of case series and case reports for cocamidopropyl betaine (CAPB).
| Study | Year (Range) | Country | Sex | Age | Occupation | Working Years | Own Product Tested |
|---|---|---|---|---|---|---|---|
| Korting et al. [ | 1992 | Germany | 2 females | n/a | hairdresser | n/a | shampoos |
| Taniguchi et al. [ | 1992 | Japan | male | 22 | hairdresser | n/a | shampoos |
| Lin-Hui and Sun [ | 1998 | Taiwan | female | 47 | hairdresser | 30 | shampoo, hair dye |
| Ross and White [ | 1991 | UK | female | 60 | n/a | n/a | eye make-up remover |
| Brand and Delaney [ | 1998 | Australia | female | 50 | n/a | n/a | shampoos |
| Mowad [ | 2001 | USA | male | 75 | n/a | n/a | shampoo |
| McFadden [ | 2001 | UK | 6 females | 26–69 | n/a | n/a | eye make-up remover, liquid soap |
| Moreau and Sasseville [ | 2004 | Canada | female | 39 | n/a | n/a | facial creams |
n/a, not applicable; UK, United Kingdom; USA, United States of America.